Combined associations of a healthy lifestyle and body mass index with colorectal cancer recurrence and survival: a cohort study
Menée à partir de données portant sur 1 098 patients atteints d'un cancer colorectal de stade I à III, cette étude de cohorte analyse l'association entre un mode de vie sain (statut tabagique, activité physique, adhésion à un régime de type méditerranéen), l'indice de masse corporelle et la survie sans récidive ainsi que la survie globale
Résumé en anglais
Purpose: Colorectal cancer (CRC) risk is associated with modifiable lifestyle factors including smoking, physical inactivity, Western diet, and excess body weight. The impact of lifestyle factors on survival is less known. A cohort study was conducted to investigate the combined effects of a healthy lifestyle and body mass index on prognosis following CRC diagnosis.
Methods: Treatment and follow-up data were collected from the patient files of 1098 participants from the Colorectal cancer low-risk study cohort including stage I-III CRC patients. A healthy lifestyle and BMI (HL) score was computed using self-reported data on smoking status, physical activity, adherence to a Mediterranean diet pattern, and BMI, and divided into four categories ranging from least to most healthy. Survival analyses were performed to assess recurrence-free survival and overall survival across categories of exposure, using the Kaplan–Meier method and Cox proportional hazards models adjusted for age, sex, and educational level.
Results: Among 1098 participants with stage I-III CRC, 233 (21.2%) had an HL score of 0–1 (least healthy), 354 (32.2%) HL score of 2, 357 (32.5%) HL score of 3 and 154 (14.0) HL score 4 (most healthy). Patients with the healthiest lifestyle (HL score 4) compared to the least healthy (HL score 0–1) had an improved recurrence-free survival (HL 4 vs HL 0–1, HRadj 0.51 (95% CI 0.31–0.83) and overall survival (HL 4 vs HL 0–1, HRadj 0.52 (95% CI 0.38–0.70).
Conclusion: Adherence to a healthy lifestyle may increase the recurrence-free and overall survival of patients with stage I–III CRC.
